Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Status:
Terminated
Trial end date:
2017-12-13
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study was to determine whether treatment with ceritinib
demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic
malignancies to warrant further study.